Previous 10 | Next 10 |
UroGen Pharma (NASDAQ: URGN ): Q2 GAAP EPS of -$1.08 beats by $0.13 . More news on: UroGen Pharma Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
UGN-101 Rolling NDA Submission on Track for Q4 2019 with Planned Launch in 1H 2020 Final Topline UGN-101 Phase 3 Data from OLYMPUS Trial to be Announced in Q3 2019 Company Investor Day Scheduled for September 24, 2019 Quarterly Conference Call and Webcast to be Held on Monday...
Conference Call and Webcast Scheduled for Monday, August 12, 2019 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report second quarter 2019 financial results on Friday, August 9, 2019, prior to the open of the market. The announcement will be followed by a ...
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000 ® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effectiv...
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000 ® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effectiv...
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this Read more ...
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at three investor conferences in June: Jefferies 2019 Global Healthcare Conference Tuesday, June 4th 9:00AM Eastern Time New York, NY Goldman Sachs 40 th Annual Global Healthcare Confere...
UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Conference Call May 09, 2019 08:30 AM ET Company Participants Kate Bechtold - IR Liz Barrett - President and CEO Mark Schoenberg - CMO Peter Pfreundschuh - CFO Conference Call Participants Derek Archila - Stifel Ram Selvaraju -...
UroGen Pharma (NASDAQ: URGN ): Q1 GAAP EPS of -$1.11 beats by $0.13 . More news on: UroGen Pharma Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Completion of UGN-101 Rolling NDA Submission to the FDA On Track for 2H 2019 Pre-Commercial Activi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...